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INTRODUCTION 
 
Wilms tumour (WT) is the most common renal tumor of 
childhood typically affects children under the age of 6 years. The 
overall annual incidence of Wilms’ tumor is approximately 7.6 
cases per million children under 15 years of age. Wilms’ tumor 
accounts for 6–7% of all childhood cancers. It is the subject of 
intense academic interest due to its occurrence in paediatric age 
group with significant mortality. 
 
This has been significantly reduced with relapse free survival 
rates due to ongoing scientific research and various cooperative 
protocols like National Wilms Tumour Study Group(NWTSG), 
Society for International Paediatric oncology group(SIOP), United 
Kingdom Children Cancer Study Group(UKCCSG). 
 
New treatment protocols with addition of chemotherapy and 
radiotherapy have contributed in improving the survival especially 
in the low risk Wilms tumour. 
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Unfortunately patients with unfavourable histology, lung, liver 
metastasis, major tumour spillage and bilateral tumours have worst 
outcome.  
 
The present study is to analyse the various prognostic 
factors that determines the outcome of Wilms tumour and to 
analyse the prognostic significance of tumour staging and 
histopathology in Wilms tumour patients treated at our hospital. 
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AIMS OF THE STUDY 
 
1. To assess the various prognostic factors that determines the 
outcome of Wilms tumour. 
2. To analyze the prognostic value of histopathology in Wilms 
tumour. 
3. To analyze the prognostic significance of tumour staging in 
Wilms tumour. 
4. To identify the causes for early mortality in Wilms tumour. 
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MATERIAL AND METHODS 
 
Study design:  
It is retrospective and prospective study evaluating the 
various prognostic factors that determines the outcome of Wilms 
tumour in our hospital. 
 
Study Period: 
December 1999 to December 2009 
 
Study Centre: 
Department of Paediatric surgery , Coimbatore Medical 
College, Coimbatore. 
 
Inclusion Criteria: 
• All patients with Wilms tumour admitted between December 
1999 to December 2009 were included in this study. 
• Age group – 0 to 12 Years. 
 
Exclusion Criteria: 
• Two cases of Wilms tumour  who expired before starting the 
treatment were excluded from this study. 
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METHODOLOGY 
 
All the patients with renal mass admitted in our department 
was evaluated thoroughly by clinical examination and the following 
investigations. 
 
Laboratory Studies 
• Complete blood count 
• Basic metabolic panel, including serum calcium levels 
• Coagulation abnormalities (to rule out acquired von 
Willebrand         disease, which is coincident in up to 8% of 
individuals with Wilms tumor) 
• Liver function tests 
• Renal function tests 
• Urinalysis and urine culture 
 
Imaging Studies 
• Ultrasonography 
o Initial diagnosis of a renal or abdominal mass, possible 
renal vein or inferior vena cava (IVC) thrombus 
(Doppler flow study may be helpful in the setting of 
vascular invasion.) 
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o Information regarding liver and other kidney 
• CT scanning of the chest and abdomen 
o Differential diagnosis of a kidney tumor versus adrenal 
tumor (neuroblastoma) 
o Liver metastases 
o Status of opposite kidney 
o Lymph node assessment 
o Status of chest with respect to metastases 
• Chest radiography - As a baseline for pulmonary metastases 
• Magnetic resonance imaging 
o Typically, these tumors appear inhomogeneous on 
gadolinium-enhanced MRI, while the nephrogenic rests 
(which sometimes are precursors of Wilms tumor [WT]) 
appear as homogeneous masses. 
o MRI is also useful for magnetic resonance venography 
to aid in the diagnosis of thrombus of the renal vein of 
the IVC. 
o MRI scanning of the head is recommended in patients 
with suspected rhabdoid and clear cell carcinoma of 
the kidney. 
All following datas relating to the patients and the biolological 
characteristics of the tumour were obtained from case records. 
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These information were recorded on a separate proforma that was 
designed specifically for this study. 
• Age 
• Gender 
• Histopathology – Favourable and unfavourable 
• Tumour spillage 
• Microscopic involvement of surgical margins 
• Abdominal lymph node involvement 
• Tumour thrombus involving the Inferior Vena Cava 
Staging was assessed according to the system used by the recent 
NWTSG protocol. 
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RESULTS 
Hospital charts and surgical notes were reviewed and the 
results of 25 children with Wilms tumour were analyzed. 
Gender: 
 Number Percentage Death Percentage 
Male 12 48% 5 41% 
Female 13 52% 5 38% 
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Age Group: 
 Number Percentage Death Percentage 
0-23 Months 5 20% 3 60% 
24-47Months 12 48% 4 33% 
>48 Months 8 32% 3 37% 
 
 
 
 
10 
 
Staging  
 Number Percentage Death Percentage
Stage I 6 24% - 0% 
Stage II 5 20% 1 20% 
Stage III 8 32% 5 62% 
Stage IV 4 16% 3 75% 
Stage V 2 8% 1 50% 
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Histopathology  
 Number Percentage Death Percentage
Favourable 17 62% 3 17% 
Unfavourable 8 32% 7 87% 
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Lymph Node Involvement 
 Number Percentage Death Percentage
Not Found 9 36% - 0% 
Node Negative 4 16% 1 25% 
Node Positive 12 48% 8 68% 
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Resectability of the tumour at the time of initial diagnosis: 
 Number Percentage Death Percentage 
Yes 20 80% 6 30% 
No 5 20% 4 80% 
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Tumour Spillage 
 Number  Percentage Death Percentage 
Yes 7 28% 5 71% 
No  18 72% 5 27% 
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REVIEW OF LITERATURE 
 
Wilms' tumor is the commonest childhood renal tumor and 
accounts for 6% of all pediatric malignancies (1). It predominantly 
affects children less than five years of age, with 90% of new cases 
diagnosed before age three years. Occasionally, WT has also 
been described in teenagers and adults. 
 
Wilms' tumor normally develops in otherwise healthy 
children; however, 10% of cases occur in individuals with 
recognizable phenotypic syndromes - either overgrowth or non-
overgrowth(2). The commonest syndromes associated with WT are 
WAGR syndrome, the Beckwith-Wiedemann syndrome and the 
Denys-Drash syndrome. 
 
Several epidemiological studies have investigated parental 
occupational, environmental and lifestyle characteristics as well as 
birth weight of the child as potential risk factors for Wilms' tumor, 
but findings to date have been inconsistent and have not been 
consistently replicated in multiple, high-quality studies in different 
populations(3,4).Future epidemiologic studies may benefit from 
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more detailed exposure assessment, validated by environmental 
and biologic measurements. 
 
Cytogenetics 
Wilms' tumor is predominantly a sporadic disease. Genetic 
predisposition, however, has been demonstrated in a few patients. 
Substantial bodies of genetic and molecular studies have 
contributed important insights into understanding the pathogenesis 
of WT with several genes being implicated in its 
etiopathogenesis(5,6).  
 
The WT gene-1 (WT1) is a tumor suppressor gene located 
on the short arm of Chromosome 11 (11p13). The normal function 
of WT1 is required for normal genitourinary development and is 
important for differentiation of the renal blastema. The identification 
of this suppressor gene was made on cytogenetic analysis of 
patients with WAGR syndrome who have more than 30% risk of 
developing WT. A gene that causes aniridia (PAX-6) is located 
near the WT1 gene on Chromosome 11p13 and deletions 
encompassing the WT1 and aniridia genes explain the association 
between aniridia and WT.  
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The Denys-Drash syndrome has a 95% chance of WT 
development and is another syndrome associated with WT1 gene 
mutation. Although WT1 has a clear role in the tumorigenesis of 
WT in the above patients, only a small number of patients with 
sporadic WT have WT1 mutations suggesting that other genes are 
involved in WT development.  
 
A second WT suppressor gene, WT2, was identified at 
Chromosome 11p15. Patients with Beckwith-Wiedemann 
syndrome (BWS) have gene locus in this region and have a 5% 
risk of developing WT.  
 
In addition to the two genetic loci on Chromosome 11, 
familial WT predisposition at FWT 1 (17q) and FWT 2 (19q) loci 
has been identified. Several other genetic loci have been 
implicated in WT by Loss of heterozygosity (LOH) studies or by the 
presence of germline translocations, including 16q, 7p, 11q, 22q 
and loss of 4q. 
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Clinical Presentation 
There are no specific clinical features of WT. Most commonly 
patients present with a palpable abdominal mass accidentally 
noted by the parents or in the course of a routine clinical 
examination. However, about one-third of patients present with 
abdominal pain, anorexia, vomiting, malaise or a combination of 
these symptoms. Gross or microscopic hematuria is found in 30% 
of patients. 
 
 
3YR OLD FEMALE CHILD PRESENT AS MASS ABDOMEN 
In rare cases of renal vein or caval extension of tumor, 
varicocele, hepatomegaly, ascites or congestive heart failure may 
be present. Hypertension is present in about 25% and is attributed 
to increase in renin activity.  
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Occasional presentation in a subset of patients is rapid 
enlargement of the abdomen associated with fever, anemia and 
hypertension as a result of sudden subcapsular hemorrhage. In 
rare cases of renal vein or caval extension of tumor, varicocele, 
hepatomegaly, ascites or congestive heart failure may be present. 
Acquired von Willebrand's disease may occur in less than 10% of 
patients. 
Associated anomalies and Syndromes present in 15% of 
patients with Wilms Tumour 
ANIRIDIA 
  
HEMIHYPERTROPHY 
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Denys –Drash  syndrome  
Male pseudo-hermophroditisim, progressive glamarular 
disease with Wilms tumour. 
 
Bloom syndrome: 
Diminished growth & immunity, fascial telangiectasia, trisomy 
18, imperforate anus with RUF 
 
WAGR syndrome 
Wilms tumour, aniridia, ambiguous genitalia and mental 
retardation. 
 
Beckwith-Wiedemann syndrome  
Macroglossia, gigantism, and umbilical hernia. 
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IMAGING 
Although most patients undergo Ultrasonography (US) as the 
initial imaging study, the conventional imaging modality for WT has 
been a computed tomography (CT) scan. It ascertains features of 
the renal mass, the extent, status and function of the contralateral 
kidney and intravascular extension of tumor. Real-time 
ultrasonography can identify the patency and presence of tumor 
thrombus in the renal vein and the inferior vena cava.  
 
The value of MRI in this disorder is yet to be established, 
however, a recent study indicated contrast-enhanced CT and T1-
W MR images to be of similar potential and superior to US in the 
diagnosis of nephroblastomatosis and due to the significant 
radiation dose of serial CT, MR imaging should be the method of 
choice wherever it is available(7). 
 
The role of CT scan in the evaluation and subsequent 
management of pulmonary lesion found only on chest CT scan is 
controversial and its prognostic importance is equivocal(8,9). A 
recent review from National Wilms' Tumor Study (NWTS) 5 of 
children who had CT-only lung disease demonstrated an inferior 
outcome for patients treated with vincristine and dactinomycin 
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(two-drug therapy) only, with or without pulmonary radiation 
therapy (RT), compared with those who received doxorubicin 
(DOX) in addition to vincristine and dactinomycin (three-drug 
therapy)(10). 
 
 In addition, there appeared to be no beneficial effect from 
lung irradiation on the outcome of CT-only patients when 
chemotherapy was considered. Another study demonstrated CT-
only lesions are not invariably tumor, demonstrating the need for 
histopathological confirmation(11).  
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STAGING 
Due to the different treatment schedules adopted by the two 
large cooperative study groups, two major staging systems are 
currently used. A forthright, surgery-based system developed by 
the NWTSG  and a delayed surgery-based system developed by 
SIOP Although a direct comparison is not practical due to the 
difference in surgical timing, both staging systems are valuable in 
predicting outcomes. 
 
NWTS STAGING SYSTEM 
Stage I:  
            The tumor is limited to the kidney and was completely 
excised. The renal capsule has an intact outer surface.  
            The tumor was not ruptured or biopsied prior to removal 
(fine-needle aspiration biopsies are excluded from this restriction).  
            The vessels of the renal sinus are not involved.  
            There is no evidence of tumor at or beyond the margins of 
resection. 
 
Stage II:  
The tumor extends beyond the kidney, but was completely 
excised.  
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There may be regional extension of tumor (i.e. penetration of 
the renal capsule or extensive invasion of the renal sinus).  
             The blood vessels outside the renal parenchyma, including 
those of the renal sinus, may contain tumor.   
The tumor was biopsied (except for fine-needle aspiration), 
or there was spillage of tumor before or during surgery that is 
confined to the flank, and does not involve the peritoneal surface.  
There must be no evidence of tumor at or beyond the 
margins of resection. 
 
Stage III:  
Residual non-hematogenous tumor is present, and confined 
to the abdomen.  
Any one of the following may occur:  
1. Lymph nodes within the abdomen or pelvis are found to be 
involved by tumor (renal hilar, para-aortic, or beyond). (Lymph 
node involvement in the thorax, or other extra-abdominal sites 
would be a criterion for stage IV.)  
2. The tumor has penetrated through the peritoneal surface.  
3. Tumor implants are found on the peritoneal surface.  
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4. Gross or microscopic tumor remains postoperatively (e.g. 
tumor cells are found at the margin of surgical resection on 
microscopic examination).  
5. The tumor is not completely resectable because of local 
infiltration into vital structures.  
6. Tumor spill not confined to the flank occurred either before or 
during surgery. 
 
Stage IV:  
Hematogenous metastases (lung, liver, bone, brain, etc.), or 
lymph node metastases outside the abdominopelvic region are 
present. 
 
Stage V:  
Bilateral renal involvement is present at diagnosis. An 
attempt should be made to stage each side according to the above 
criteria on the basis of the extent of disease prior to biopsy or 
treatment. 
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SIOP STAGING SYSTEM 
Stage I 
• Tumour limited to the kidney or, if outside the normal kidney 
contour, surrounded with a fibrous pseudocapsule that may 
be infiltrated with tumor that does not reach the outer 
surface, and is completely resected. 
• Tumor may protrude into the renal pelvis and ureter, but not 
infiltrate their walls 
• Vessels of the renal sinus are uninvolved 
• Intrarenal vessels may be involved 
 
Stage II 
• Tumor extends beyond kidney or penetrates through renal 
capsule and / or fibrous pseudocapsule into perirenal fat, but 
completely resected. 
• Tumour infiltrates renal sinus and / or invades blood and 
lymphatic vessels outside the renal parenchyma, but is 
completely resected. 
• Tumor infiltrates adjacent organs or vena cava but is 
completely resected. 
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Stage III 
• Incomplete tumor excision that extends beyond resection 
margins (gross or microscopic tumor remains) 
• Tumor penetrates the peritoneal surface 
• Tumor implants on peritoneal surface 
• Tumor thrombi present at resection margins of vessels or 
ureter, transected or removed piecemeal by the surgeon 
• The tumor has been surgically biopsied before preoperative 
chemotheraphy or surgery 
 
Stage IV 
• Hematogenous metastases (lung, liver, bone, brain etc.,) or 
lymph node metastases outside the abdominal and pelvic 
region. 
 
Stage V 
• Bilateral renal tumours present at diagnosis 
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PATHOLOGY  
A classic WT is triphasic, with variable proportions of 
blastemal, stromal and epithelial components. Some WT are 
monophasic and have a highly aggressive biological behavior. 
Histological features in the nephrectomy specimen provide 
important prognostic information for planning treatment. Presence 
of nuclear atypia, focal/diffuse anaplasia and sarcomatous 
elements indicate an unfavorable histology, seen in about 5% of all 
WT(12). These account for nearly half of all deaths from this 
disease. Anaplasia is a marker of resistance to chemotherapy but 
whether it actually signifies aggressiveness in unknown. 
 
 
 
GROSS APPEARANCE OF THE REMOVED SPECIMEN 
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LOW-POWER MICROSCOPIC VIEW SHOWING A 
COMBINATION OF BLASTEMA, STROMA, EPITHELIAL 
TUBULAR FORMATION, AND IMMATURE GLOMERULI. 
 
The SIOP trials recognized three prognostic groups of renal 
tumors of childhood: low-risk, intermediate-risk and high-risk 
tumors(13).  
 
It is important to look for nephrogenic rests in the 
nephrectomy specimen of WT. A nephrogenic rest is defined as 
the persistence of metanephric tissues in the kidney after the 36 th 
week of gestation. As they are found in 30-40% of the kidneys 
removed for WT they may be considered as precursor of WT(14). 
Nephrogenic rests are subclassified by their position within the 
renal lobe  as perilobar or intralobar.  
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HIGH-POWER VIEW SHOWING BLASTEMA, STROMA, AND 
IMMATURE TUBULAR FORMATIONS 
 
 
The presence of multiple nephrogenic rests is termed as 
nephroblastomatosis. Only a small number develop clonal 
transformation into WT while the rest involute spontaneously. The 
presence of nephrogenic rests within a kidney resected for a 
Wilms' tumor indicates the need for monitoring the contralateral 
kidney for tumor development, particularly in young infants(15)  
 
Prognostic Factors 
The tumor stage at diagnosis, histological features (favorable 
vs. unfavorable, presence of diffuse anaplasia) and patient age are 
the most important prognostic determinants which impact on 
treatment selection and oncological outcome(16). The LOH at 
chromosome 1p and 16q was prospectively analyzed by NWTS-
31 
 
5(17).  Tumor-specific LOH for both chromosomes was found in 
approximately 5% of patients with FH WT and was associated with 
increased risk of relapse and death. 
 
TREATMENT 
Wilms' tumor can be considered a model for successful 
multidisciplinary management of cancer, with improvement in 
survival from a mere 30% in the 1930s to more than 85% at 
present. It is also an ideal example wherein the treatment 
protocols have been devised and modified repeatedly depending 
on evidence emerging from randomized trials conducted by 
several cooperative groups and individual institutions.  
 
The most important contributions have been from NWTSG 
and SIOP, with large numbers of patients enrolled in their studies 
but with a philosophical difference in their treatment approach. The 
NWTSG recommends primary surgery before administration of 
chemotherapy while SIOP advocates administration of four weeks 
of chemotherapy prior to surgery.  
 
The former approach allows accurate documentation of 
histology and tumor extent prior to chemotherapy and also enables 
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the collection of untreated tumor for biology studies and provides 
an unadulterated view of the tumor's molecular biology. The latter 
approach downstages the disease, makes surgery easier and 
reduces the chances of spillage with consequent reduction in 
abdominal and distant relapse but carries a risk of non-WT 
histology being present in the primary tumor. Besides, histologic 
response to chemotherapy can be assessed postoperatively which 
provides valuable prognostic information(12).  
 
The NWTSG advocates preoperative chemotherapy only in 
the presence of WT in a solitary or horseshoe kidney, bilateral 
tumors, venal caval thrombus above hepatic veins or severely 
symptomatic lung metastases(18). Since both these approaches 
have yielded excellent results, there is still a debate concerning the 
preferred approach, but individualization of treatment based on 
tumor size and extent, general condition of the patient and 
surgeon's experience would probably be needed for best outcome. 
 
Surgery  
The timing of surgery with regards to preoperative therapy 
has varied between the European and the North American group. 
Nevertheless surgical resection is an important constituent in the 
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multimodal management of WT. Radical nephrectomy is the 
standard of care for these patients with resectable tumors. A 
transperitoneal route is preferred to provide adequate exposure for 
complete staging, which includes inspection for local tumor 
extension, hilar and regional lymph nodes, liver metastases and 
peritoneal seedlings.  
 
Debates about the exploration of the contralateral kidney at 
surgery exist but evidence now suggests it can be omitted. Data 
from the NWTS 4 study showed that omission of routine 
exploration does not affect the outcome or management of newly 
diagnosed WT, if adequate preoperative CT or MRI is obtained(19). 
Prevention of tumor spillage should be of prime concern as this 
has a bearing in upstaging the tumor, hence gentle handling and 
careful removal is mandatory(20).  
 
The IVC and the renal vein should be palpated for the 
presence of tumor thrombus, which if present (renal vein thrombus 
seen in about 6% patients) should removed en bloc with the 
kidney(21). Generally, WT does not infiltrate the adjoining 
structures, hence a radical en bloc resection is rarely needed, 
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however, a wedge resection if can be performed safely may help in 
down-staging the tumor to Stage II.  
 
As regards lymph node dissection, sampling of suspicious 
lymph node is recommended instead of a formal lymph node 
dissection. An adequate and careful surgical resection is 
mandatory for optimal treatment outcome since incomplete 
resection, tumor spillage and omission of lymph node sampling are 
all reported to be associated with abdominal recurrence. Although 
surgical complications have significantly reduced, surgical 
morbidity should not be overlooked. Indeed surgical specialists 
who primarily treat children can perform these operations with 
lower surgical morbidity(20). Tumor spillage and intraperitoneal 
dissemination increases the risk of intra abdominal relapse but the 
current data suggests that overall survival is not adversely 
affected(20).  
 
Partial nephrectomy in the routine management of WT has 
not gained popularity. The reasons being most WT are large or 
centrally located making only less than 5% eligible for partial 
nephrectomy at presentation and even after preoperative 
chemotherapy only about 10% would be feasible for a nephron-
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sparing surgery(22,23). These surgeries carry a risk of leaving behind 
nephrogenic rest in addition to other procedure-related 
complications. Besides, the rate of renal failure in patients with 
unilateral WT is less than 1%(24).   
 
Hence partial nephrectomy is only recommended for patients 
with synchronous or metachronous bilateral tumors, tumors in 
solitary kidneys, renal insufficiency of any etiology and children 
with risk of multiple neoplasms such as in BWS. Laparoscopic 
nephrectomy with lymph node sampling has been described in the 
literature but long-term experience is lacking(25).  
 
CHEMOTHERAPY  
Chemotherapy plays a very important role in the 
management of WT. The current first line drugs for WT are 
vincristine, dactinomycin and doxorubicin. The second line drugs 
for non-responsive or relapsed disease are ifosphamide, 
etoposide, carboplatin and cyclophosphamide. Large cooperative 
groups have different chronology for deliverance of chemotherapy, 
drug combination and duration, which have been refined over 
successive trials to optimize survival rates while minimizing acute 
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and long-term toxicities. It is indeed noteworthy that despite these 
differences, the survival results amongst all groups are similar.  
 
The SIOP and UKCCSG group has favored the use of 
preoperative chemotherapy in an attempt to down-stage the tumor, 
whereas the NWTSG advocates upfront nephrectomy without 
preoperative therapy in order to precisely identify the tumor stage. 
 
Radiotherapy  
As a result of the NWTSG and SIOP studies the role of 
surgery has been customized though not eliminated. Radiation 
was an important treatment modality in preoperative and adjuvant 
settings in the earlier studies. With subsequent refinement in 
therapy with an aim of maximizing cure and reducing morbidity, 
there are now precise indications for adjuvant radiotherapy. The 
current standard of care includes flank/abdominal irradiation 
(10·8Gy in six fractions) for Stage III favorable-histology (FH) 
tumors and Stage II-III diffuse anaplastic WT(1).  
 
The role of lung irradiation in metastatic disease is 
unresolved with difference among the groups. The NWTSG 
continues to administer whole lung irradiation (12Gy in eight 
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fractions) in patients with pulmonary metastases, while the SIOP 
group advocates omission of radiotherapy for patients whose lung 
metastases disappear completely after six weeks of 
prenephrectomy chemotherapy with vincristine, dactinomycin and 
doxorubicin.  
 
The role of pulmonary irradiation in children with pulmonary 
metastases visible on CT but not chest radiograph is further 
mystified. Use of conformal radiotherapy as well as IMRT has led 
to dose escalation without increase in morbidity. Similarly, use of 
high-dose intraoperative radiation therapy for WT has been 
reported.(2) 
 
TUMOR STAGE AND TREATMENT 
The histologic grade and stage of the tumor are the most 
important determinants of outcome in Wilms' tumor. An accurate 
intraoperative staging is required to assess the requirements for 
postoperative treatment with chemotherapy or radiotherapy. 
 
Stage I FH  
Stage I WT FH has an excellent prognosis. The NWTSG 
recommends primary surgery followed by adjuvant two-drug 
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chemotherapy (vincristine and pulse intensive dactinomycin) for 18 
weeks based on NWTSG 1-3 trials(26,27,28),  whereas the SIOP 
approach uses the same drugs either side of surgery for a total of 
eight weeks based on several SIOP studies. (29, 30) Radiation 
therapy is not necessary in these patients if they receive adjuvant 
chemotherapy, as demonstrated by the initial three NWTSG trials 
(26,27,28) as well as the SIOP 5 trial.(31) 
 
Surgery without chemotherapy was evaluated in NWTS-5 in 
a select group of patients with highly favorable features (infants 
younger than 24 months and whose nephrectomy specimen 
weighed less than 550g(32). The study was designed with a 
stringent stopping rule (interim analysis of RFS ≤90%) and 
reported 13.5% relapse rate at two years, mandating the closure of 
the study. Most patients could be successfully salvaged with 
chemotherapy, however, with a two-year overall survival (OS) rate 
of 100%. In the light of this, further studies are re-evaluating the 
role of nephrectomy alone in this highly selected group of patients. 
 
The NWTS-3 (28) reported 92.5% RFS and 97.6% OS at 16 
years and NWTS- 5 (33) reported 92.4% RFS and 98.3% OS at four 
years for these patients. Similarly the SIOP 93-01 (34) has reported 
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a five-year RFS rate of 88.3% and five-year OS rate of 97% in 
these patients. The UKWG 2-3 reported 86.5% EFS and 94.7% 
OS at four years(35,36). 
 
Stage II  
Currently, the NWTS-5 (32,33) recommends primary surgery 
followed by 18 weeks of chemotherapy with vincristine and pulse-
intensive dactinomycin. Addition of postoperative radiotherapy 
(RT) or doxorubicin was not shown to impart survival benefit in the 
NWTS-3. (30) The SIOP 93-01 trial (34) recommends preoperative 
four weeks of chemotherapy with vincristine and pulse-intensive 
dactinomycin and addition of doxorubicin in postoperative 
chemotherapy for 27 weeks. Node-negative patients do not 
receive postoperative RT provided they receive postoperative 
epirubicin (SIOP-9) (30) while node-positive receive 15Gy RT to the 
tumor bed in addition to three-drug chemotherapy. 
 
The NWTS -3 reported 89.6% RFS and 92.9% OS at 16 
years and the NWTS- 4 (37)] trial 83.6% RFS and 93.8% OS at eight 
years for Stage II FH WT. The SIOP-9 reported 85% RFS and 
88% OS at two years in node-negative stage patients. 
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Stage III  
The NWTS-5 recommends surgery followed by abdominal 
radiation (10.8Gy) and 24 weeks of chemotherapy with vincristine, 
doxorubicin and pulse-intensive dactinomycin. The SIOP 93-01 
trial recommends preoperative four weeks of chemotherapy with 
vincristine and pulse-intensive dactinomycin and 27 weeks of 
three-drug chemotherapy with vincristine, doxorubicin and 
dactinomycin in addition to postoperative 15Gy abdominal 
radiotherapy. 
 
The results of the NWTS-3 trial showed that the addition of 
doxorubicin to chemotherapy resulted in reduction of radiation 
dose from 20Gy to 10Gy for Stage III/FH patients. The NWTS-4 
trial reported six months chemotherapy to be sufficient for Stage 
III/FH patients. 
 
The NWTS-3 has reported 80.4% RFS and 86.2% OS at 16 
years and NWTS- 4 reported 88.9% RFS and 93% OS at eight 
years for Stage III FH patients. The SIOP-9 reported 71% RFS and 
85% OS at two years in patients with Stage III and Stage II node-
positive FH patients. 
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Stage IV  
The NWTSG recommends nephrectomy with lymph node 
sampling, abdominal radiation 10.8Gy according to local stage of 
renal tumor (i.e. for Stage III), and bilateral pulmonary radiation 
12Gy for patients with chest X-ray evidence of pulmonary 
metastases and 24 weeks of chemotherapy with vincristine, 
doxorubicin and pulse-intensive dactinomycin. The NWTS-3 
reported 76.5% RFS and 79.5% OS at 16 years and NWTS- 4 
reported two-year RFS of 80.6% and OS of 89.5% for Stage IV FH 
patients. 
The SIOP advocates six weeks of preoperative 
chemotherapy with vincristine, dactinomycin and doxorubicin 
followed by surgery. Those who attain CR by Week 9 receive 27 
weeks of three-drug chemotherapy as the preoperative one 
without radiation therapy. Those whose pulmonary metastases do 
not respond completely to chemotherapy, with or without surgical 
excision of residual metastases by Week 9 are advised 
postoperative 12Gy whole-lung irradiation and four-drug 
chemotherapy (ifosphamide, carboplatin, etoposide and 
doxorubicin) for 37 weeks. This helps in limiting the number of 
children who are exposed to whole-lung radiation, with its inherent 
associated toxicity. (38) The SIOP reported 83% four year RFS.  
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Management of Anaplastic Tumors 
Stage I:  
Focal or diffuse anaplastic tumors: The NWTS- 5 trial has 
reported 69.5% RFS and 82.6% OS at four years for Atage I focal or 
diffuse anaplastic histology patients, using surgery followed by 18 
weeks of chemotherapy with vincristine and pulse-intensive 
dactinomycin. However, due to these suboptimal results, the future 
studies plan to include abdominal radiation and doxorubicin into the 
treatment regimen of these patients. The SIOP approach uses the 
same drugs either side of nephrectomy for a total of eight weeks. 
 
Stages II-IV:  
For patients with Stage II-IV WT with focal anaplasia, NWTSG-5 
advocates primary surgery followed by abdominal radiation and 
adjuvant three-drug chemotherapy with vincristine, doxorubicin and 
dactinomycin. For those with diffuse anaplasia, patients are advised 
postoperative abdominal radiation and adjuvant chemotherapy 
regimen consisting of vincristine, doxorubicin and cyclophosphamide 
alternating with cyclophosphamide and etoposide. This change of 
chemotherapy was warranted due to the results of NWTS-4 which 
showed that the four-year RFS was considerably improved (27% to 
55%) with the addition of cyclophosphamide. 
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The NWTS- 5 reported four-year RFS of 55.1% and 74.9% 
for patients with diffuse and focal anaplasia respectively. Four-year 
RFS estimates for Stage II, III, IV were 82.1%, 68.3% and 37.5% 
respectively. 
 
Stage V  
Synchronous bilateral WT account for 6% of all WT and also 
pose a special challenge(1). The goal of therapy for patients with 
bilateral disease, beyond cure of the tumor, is to spare renal 
parenchyma to avoid significant renal insufficiency and hence the 
treatment must be individualized.  
 
The NWTS-2 and 3 studies have demonstrated no difference 
in survival for children who undergo initial bilateral biopsy followed 
by chemotherapy and then surgical resection compared with 
patients who have initial resection followed by chemotherapy(39). 
However, preoperative chemotherapy often results in significant 
reduction in tumor size, thereby facilitating subsequent renal 
salvage. The NWTS-4 reported only 8.2% risk of local relapse 
following nephron-sparing surgery(40).  
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The NWTS-5 recommendations for the management of 
bilateral WT include initial biopsy and local staging followed by 
chemotherapy (according to abdominal stage and histologic 
features) and second-look surgery at Week five(12). Additional 
radiation and chemotherapy maybe given if indicated but the 
surgery must be completed by 12 weeks from diagnosis to prevent 
development of drug-resistant clones. 
 
Initial treatment is with vincristine and dactinomycin if the 
renal tumors are of favorable histology and not more extensive 
than Stage II. Those with higher stage and favorable histology 
disease should receive doxorubicin, vincristine and dactinomycin 
and those with anaplastic histology should receive 
cyclophosphamide in addition to vincristine, doxorubicin and 
etoposide. Following six weeks of chemotherapy, the patient 
should be reassessed. If serial imaging studies show no further 
reduction in tumor, a second-look surgical procedure should be 
performed (partial nephrectomy on one side if possible) if negative 
margins can be obtained; otherwise, another biopsy should be 
done to confirm viable tumor(41).  
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Chemotherapy and/or radiation therapy following the second-
look operation is dependent on the response to initial therapy, with 
more aggressive therapy required for patients with inadequate 
response to initial therapy observed at the second procedure. 
Radical nephrectomy is recommended when nephron-sparing 
surgery is not possible. Approximately 10% of patients with 
bilateral tumors have anaplastic histology and may benefit from 
more aggressive chemotherapy and radiation therapy and an 
aggressive surgical approach at the second-look operation. 
 
Renal transplantation for children with WT is usually delayed 
until one to two years have passed without evidence of 
malignancy(42).   
 
Experience from an Indian Center  
Bhagwat et al. (2005) reported their experience from a major 
oncology tertiary care referral center in India(43). At their center, 
Wilms' tumor constitutes 3.5% of approximately 800 new pediatric 
cancers registered every year and is the most common solid tumor 
after brain tumors and neuroblastoma.  
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In the earlier years, many of their patients were referred to 
their institute after primary surgery performed elsewhere, leading 
to a considerable delay in starting adjuvant treatment. However, in 
recent times, the majority of patients were operated per primum at 
their center. Whenever surgery was done outside, every effort was 
made to stage the disease based on the referring clinician's 
preoperative and intraoperative examination findings and imaging 
studies. All patients were evaluated in a multidisciplinary Pediatric 
Oncology tumor board and treated as per the standard institutional 
protocol which included three-drug chemotherapy (vincristine, 
dactinomycin and doxorubicin) for all the patients as given for 
advanced stages in the NWTS-4 to compensate for lacunae in 
staging.  
 
The overall survival and relapse-free survival of 118 WT 
patients treated over a 10-year period were 77.6% and 73.4% at 
10 years respectively. The overall survivals for Stages I-IV were 
83%, 81%, 47% and 75% respectively. These results need to be 
seen in light of the fact that many patients during this period 
underwent surgery at an outside center, with incomplete staging, 
inadequate surgery or tumor spillage during surgery. 
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RECURRENT WT  
The prognosis of recurrent WT used to be dismal, with the 
majority of patients receiving the same treatment at salvage as 
their primary treatment and with survival rates of less than 30% 
despite standard therapy by current standards (judicious surgery, 
chemotherapy with or without radiation therapy). However, in 
recent times, drugs like platinum compounds, ifosphamide, 
cyclophosphamide, etoposide etc and their combinations have 
shown considerable activity in patients with relapsed WT. Post-
relapse survival rates of 50-60% have been reported with 
ifosphamide, etoposide and carboplatin (ICE) chemotherapy(44).  
 
Factors which predict better survival are relapse-free interval 
of more than 12 months, low stage of primary disease, low 
metastatic burden, two-drug chemotherapy and no previous 
radiation to tumor bed(45). Complete resection of the recurrent 
lesion(s) has also been shown to be a favorable prognostic factor 
but whether it reflects only low-volume recurrent disease rather 
than actual survival benefit is yet debatable(44). High-dose 
chemotherapy with autologous stem cell rescue is being tried in 
clinical trials but is presently experimental(46).  
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Novel drugs and strategies are needed to improve clinical 
outcome in this group of patients. Metachronous tumors in the 
contralateral kidney account for 2% of WT, with children younger 
than 12 months with perilobar nephrogenic rests at a higher risk(47). 
The contralateral tumors need to be treated independently as the 
tumors in the first kidney. Although patients with metachronous 
tumors have a worse survival than those with synchronous tumors 
(five and 10-year OS of 49.1% and 47.2%); in the former group, 
those developing after 18 months of initial diagnosis fare better 
than those developing earlier (10 year OS 55.2% vs. 39.6%)(49).  
Long-Term Sequele  
With long-term follow-up data being available in a large 
number of survivors of WT, the long-term sequele of treatment are 
becoming better defined. Renal failure after surgical management 
of unilateral WT is rare. Cardiac problems secondary to 
anthracycline administration compounded by whole-lung 
radiotherapy as well as pulmonary complications secondary to 
whole-lung radiotherapy are real concerns and need to be 
addressed(49). Gonadal dysfunction secondary to chemo and/or 
radiotherapy may occur. Children treated for WT are also at an 
increased risk of second malignancy, especially if they have also 
received radiotherapy in addition to chemotherapy(1). 
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DISCUSSION 
 
The development of effective systemic chemotherapy in the 
1960s rapidly changed the outcome and approach to treatment of 
Wilms’ tumor. Randomized clinical trials have been conducted by 
NWTSG, SIOP, and the United Kingdom Children’s Cancer Study 
Group (UKCCSG) to determine the appropriate role for each of the 
therapeutic modalities available. Patients are stratified into 
different treatment groups based on extent of disease and 
histopathologic features. The goals of these trials are to allow a 
reduction in the intensity of therapy for most patients, while 
maintaining overall survival, and to decrease potential late 
sequelae. 
 
 After instituting the various recent modalities of treatment in 
Wilms tumour, the overall survival rate significantly increased from 
20% in 1920 to 90 % in 2000 as per recent NWTSG reports. 
 
In our study the overall survival rate is 60% (15 out of 25 
children). 
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In another report from our country (Bhagawat et al..)43 shows 
83% overall survival rate in a large cohort of patients. Marilia 
Fornaciari et al.. from Brazil report 84.6% overall survival rate in 
132 patients. 
 
Most of our cases present lately and majority of the cases 
were in advanced stages (14 of 25 were stage 3 and stage 4), 
which may be the possible cause for lower survival rates. 
  
Another possible explanation is – loss of Hetrozycocity(LOH) 
i.e., chromosomal loss in 1p and 16q may be the caused for poor 
progonostic outcome. 
        
Five children with stage I tumour and three children with 
stage II tumours have survived more than 5 years. This is 
comparable with recents NWTSG and SIOP trials. 
 
Gender: 
Out of the 25 children 13 were female and 12 were male. 
Male female ratio is almost equal and the mortality rate is also 
comparable with both groups(41% Males and 38% Females). So 
gender has no prognostic significance in our study. 
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Age Group: 
More number of deaths(60%)  have occurred in less than 23 
months age group(3 out of 5 cases), but in the Brazilian study and 
recent NWTSG reports prognosis is good in this age group(10% 
mortality in Brazilian Study(50)). Again advanced stages and 
unfavourable histology in 2 children maybe the possible 
explanation for higher mortality. 
       
Mortality in later age group 24 to 47 months and more than 
48 months is 33% and 37% respectively. This is comparable with 
Brazilian study. 
  
Tumour staging is one of the main prognostic indicator that 
determines the outcome of treatment and survival in Wilms 
tumour. The survival rate based on staging is comparable to other 
studies except in Stage III tumours. 
 Our 
Study 
Brazilian Study 
(1999 - 2000) 
NWTSG  
Reports (2005) 
UKCCSG 
(2000) 
STAGE I 100% 100% 96% 94% 
STAGE II 80% 94.2% 86% 91% 
STAGE III 38% 51% 81% 84% 
STAGE IV 25% 31.3% 75% 70% 
STAGE V 50% -- -- -- 
52 
 
Even though it is difficult to explain, the higher mortaility rate 
in our group compared to NWTS results, irregular follow-up for the 
treatment, and toxicity to chemotheraphy may be possible 
explanations for this. So early cases in Stage I and Stage II 
tumours response well to treatment and prognosis good.  
  
Children with favourable histology (Triphasic pattern and no 
anaplasia) has good prognostic outcome. Only 3 deaths occurred 
out of 17 cases in our group as comparable to higher mortality rate 
(87%) in unfavourable histology group. (Focal or diffuse 
anaplasia). 
 
 This observation with comparable with Brazelian study. But 
NWTS reports the mortality rate in unfavourable histology group is 
40%.  
 
 In our series, 5 patients had received pre-operative 
chemotheraphy. Of this 5 cases, only 1 patient had remnant of 
blastimal elements in final pathology report. That patient expired. 
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In 2002, SIOP trials noted that certain histology features that 
remain after pre-operative chemotheraphy, such as blastema or 
prognostic significance whereas others not. 
 
Therefore in the further SIOP trials, a revised classification of 
renal tumours to be followed for the treatment purposes.  
• Completely necrotic (low risk group) 
• Blastemic (high risk group) 
• Others (Intermediate group) 
 
Resectability of the tumour completely at the time of initial 
surgery has significance prognostic value in our observation. 
Among the 25 cases, 20 cases were completely resectable, and 
mortality rate in this group, only 30% has comparable to 80% 
mortality rate when the tumour is inoperable.  
 
 Early mortality in Wilms tumour occur in 7 of our cases. 
Tumour bed recurrence occur in 2 of our cases. Out of the 9 
cases, tumour spillage occur in 7 cases and surgical margin 
positivity in 3 cases.  
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Tumour spillage and surgical margin positivity were the 
attributed cause for early mortality, and tumour bed recurrence in 
our observation. 
 
As per recent NWTS report 10% of patients has poor 
prognostic variable including  
• Unfavourbale histology 
• Chromosome loss in 1p and 16q (loss of Hetrozycocity) 
• Diploidy 
 
However, gene mapping facilities are not available in our 
hospital, the prognostic significance of these factors are not able to 
study. 
 
IVC Extension: 
 Tumour thrombus in IVC found in 3 of our patients, in all 
patients tumour thrombus was removed enblock. All 3 patients 
were survived. So the tumour thrombus involvement below the 
hepatic veins has not affect the survival of the patients.  
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Syndomic Association: 
 In our series, only 1 patient had aniridia and nystagmus this 
patient is surviving more than 5 years. Otherwise, none of our 
patients had any syndromic association. 
 
Tumour in Horse Shoe Kidney: 
 One patient in Wilms tumour in horse shoe kidney. The 
tumour was confined to one pole of the kidney (Stage I). This 
patient was treated with nephrectomy and chemotheraphy. He is 
surviving for more than 3 years. 
 
Bilateral tumours: 
 Two of our patients had bilateral tumours. One patient had 
Stage III on right side and Stage II on left side. This patient was 
treated with right nephrectomy followed by chemotheraphy and 
radiotheraphy who has expired after 6 months. In another patient 
both side Staged tumour treated with chemotheraphy and 
radiotheraphy, surviving more than 3 years. 2 patients had 
recurrent Wilms tumour treated with solvage chemotheraphy (ICE 
Regimen – Ifospamide, Cisplatim, Etoposide).  
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One patient had liver metastasis after completion of the 
chemotheraphy who was also treated with salvage 
chemotheraphy. She survives more than 2 years with secondaries.  
  
To summarize our experience, tumour staging and 
histopathology are the two main prognostic indicator that 
determines the survival of Wilms tumour. 
  
Higher mortality rate was found in less than 24 months age 
group and older children.  
 
Resectability of the tumour at the time of initial diagnosis has 
significance prognostic value. Tumours spillage and lymph nodal 
involvement are the causes of  early mortality and Wilms tumour. 
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CONCLUSION 
 
• Stage I tumours had 100% survival rate. 
• The mortality rate was higher in Stage III and Stage IV 
tumours (more than 75%). 
• The unfavourable histology group had 80% mortality rate. 
• Higher mortality rate was observed in less than 24 months 
age group. 
• Resectabilty of the tumour at the time of initial diagnosis has 
significant prognostic value.  
• Tumours spillage and lymph nodal involvement are 
associated with early mortality and recurrent tumour. 
• Considering the constraints of the size of the study, it needs 
further follow-up to assess the long term prognostic 
variables. 
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S.No. Name Age Sex Side Stage Pathology Tumour Spillage LN Survival
1. Priya 3½ F Left Stage III Triphasic -no anaplasia ++(intraabdominal) + 6 months
2. Gowri 9½ F Left Stage II Triphasic -no anaplasia ++ - 3 months
3. Sasidharan 7½ M Left Stage II Monophasic-no anaplasia - + Survived
4. Kanagaraj 8 M Left Stage III Triphasic -no anaplasia ++ + Expired after 4 months
5. Sangameswaran 3 M Right Stage III Triphasic -no anaplasia ++ + Expired after 1 year
6. Yasodha 1½ F Left Stage I Biphasic anaplasia+ - - Survived - 5 years
7. Niketha 1½ F Right Stage III Difuse Anaplasia - + Expired after 3 months
8. Gowtham 2½ M Right Stage II Triphasic -no anaplasia - + Survived
9. Nivetha 3½ F Left Stage IV Monophasic -anaplasia+ - + Expired after 5 months
10. Prasanth 2 M Right Stage I Triphasic -no anaplasia - - Survived
11. Boopathy 4 M Left Stage IV Triphasic -difuse anaplasia - - Expired after 2 months
12. Aravindh Kumar 3 M Left Stage III Difuse Anaplasia - + Survived
13. Tamilarasan 1½ M Right Stage I Triphasic - no anaplasia - - Expired after 3 months
14. Bharath Kumar 11 M Right Stage IV Anaplasia+ - - Expired after 6 months
15. Priya 8 F Right Stage III Anaplasia+ + + Survived
16. Ajith 9 M Left Stage I Triphasic -no anaplasia - - Survived
17. Gayathri 9 F Right Stage IV Triphasic -no anaplasia + + Expired after 1 year
18. Sudha 7 F B/L [R] Stage III [L] Stage I Triphasic -no anaplasia + + Expired after 1 year
19. Boopathi 10 F Right Stage II Difuse Anaplasia + + Expired after 4 months
20. Keerthana 4 F Left Stage III Triphasic -no anaplasia - - Survived with secondaries
21. Prem Kumar 3 M Left Stage III Triphasic -no anaplasia - + Survived - 1 ½
22. Kavya 7 F Left Stage III Triphasic -no anaplasia + + Survived with secondaries
23. Rabia 3 F Left Stage I Triphasic -no anaplasia + + Survived
24. Md. Asik 4 M Left Stage I Triphasic -no anaplasia - - Survived
25. Suba 3 F B/L [R]Stage II [L]Stage I Triphasic -no anaplasia + + Survived
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